Seems this paper is promotional material for the development of new inhibitors ... the research says Xantrene stacks up fine in these areas, we're in the clinic and will have results flowing from that shortly.
The good part of the paper for us is just how widely in cancer and other medicine FTO is important.
- Forums
- General
- General Comments / Chat
Seems this paper is promotional material for the development of...
-
- There are more pages in this discussion • 5,603 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.55 |
Change
0.000(0.00%) |
Mkt cap ! $258.1M |
Open | High | Low | Value | Volume |
$1.55 | $1.55 | $1.51 | $48.23K | 31.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 174 | $1.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.55 | 5523 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 174 | 1.535 |
2 | 19398 | 1.530 |
1 | 950 | 1.525 |
2 | 10150 | 1.520 |
1 | 950 | 1.515 |
Price($) | Vol. | No. |
---|---|---|
1.550 | 5523 | 1 |
1.555 | 1553 | 2 |
1.560 | 200 | 1 |
1.565 | 3780 | 2 |
1.570 | 3000 | 1 |
Last trade - 12.18pm 23/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online